1228968-86-2

Upstream product

• 1228552-62-2 (S)-2-(4-iodo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1228968-85-1 C₂₆H₂₇N₃O₂ 
• 69610-41-9 Boc-L-Pro-H 
• 1007882-58-7 (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1228968-38-4 (S)-2-(4,5-Diiodo-1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1228968-83-9 tert-butyl (2S)-2-[5-(4'-bromobiphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidine-1-carboxylate 
• 1228968-84-0 C₂₉H₃₅N₃O₂Si 

Downstream Products

• 1228966-45-7 methyl ((1S)-1-(((2S)-2-(4-(4'-((2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)ethynyl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate 
• 1228966-46-8 C₅₄H₅₈N₈O₆ 
• 1228966-49-1 C₅₂H₅₀N₈O₄ 

Relevant academic research and scientific papers

INHIBITORS OF HCV NS5A

Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

INHIBITORS OF HCV NS5A

Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.